NewAmsterdam Pharma (NAMS) Projected to Post Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.40) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $35.24 on Wednesday. The business has a fifty day moving average price of $34.03 and a 200-day moving average price of $32.41. The company has a market capitalization of $4.00 billion, a PE ratio of -17.19 and a beta of 0.06. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $42.00.

Analyst Ratings Changes

Several research analysts have issued reports on NAMS shares. The Goldman Sachs Group lifted their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Stifel Nicolaus upped their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Needham & Company LLC boosted their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Royal Bank Of Canada upped their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Insider Buying and Selling

In other news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the transaction, the insider owned 73,481 shares of the company’s stock, valued at approximately $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 298,647 shares of company stock valued at $10,236,050. Insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Empowered Funds LLC bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at about $85,000. Persistent Asset Partners Ltd bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $138,000. Guggenheim Capital LLC purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $224,000. Finally, Orion Porfolio Solutions LLC bought a new position in NewAmsterdam Pharma during the 4th quarter worth about $230,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.